The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 11, 2019

Filed:

Jun. 03, 2016
Applicants:

Lead Pharma Holding B.v., Nijmegen, NL;

Sanofi, Paris, FR;

Assignees:

LEAD PHARMA HOLDING B.V., Nijmegen, NL;

SANOFI, Paris, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07C 311/20 (2006.01); C07C 317/44 (2006.01); C07C 317/50 (2006.01); C07D 207/06 (2006.01); C07D 209/08 (2006.01); C07D 211/16 (2006.01); C07D 211/26 (2006.01); C07D 211/60 (2006.01); C07D 213/75 (2006.01); C07D 213/82 (2006.01); C07D 215/08 (2006.01); C07D 217/02 (2006.01); C07D 223/16 (2006.01); C07D 231/40 (2006.01); C07D 241/04 (2006.01); C07D 261/08 (2006.01); C07D 277/46 (2006.01); C07D 285/135 (2006.01); C07D 295/13 (2006.01); C07D 295/192 (2006.01); C07D 307/52 (2006.01); C07D 333/36 (2006.01); C07D 417/04 (2006.01); C07D 495/04 (2006.01);
U.S. Cl.
CPC ...
C07D 213/75 (2013.01); C07C 311/20 (2013.01); C07C 317/44 (2013.01); C07C 317/50 (2013.01); C07D 207/06 (2013.01); C07D 209/08 (2013.01); C07D 211/16 (2013.01); C07D 211/26 (2013.01); C07D 211/60 (2013.01); C07D 213/82 (2013.01); C07D 215/08 (2013.01); C07D 217/02 (2013.01); C07D 223/16 (2013.01); C07D 231/40 (2013.01); C07D 241/04 (2013.01); C07D 261/08 (2013.01); C07D 277/46 (2013.01); C07D 285/135 (2013.01); C07D 295/13 (2013.01); C07D 295/192 (2013.01); C07D 307/52 (2013.01); C07D 333/36 (2013.01); C07D 417/04 (2013.01); C07D 495/04 (2013.01); C07C 2601/02 (2017.05); C07C 2601/04 (2017.05);
Abstract

Compounds according to Formula I: or a pharmaceutically acceptable salt wherein: Ais NRor CR, with Rherein; the cyclopropyl moiety with one or more methyl and one or more F; A-Aare N or CR-CR, with no more than two of the four positions A in A-Acan be simultaneously N; R-Rare described; Rand Rare independently H, F, methyl, ethyl, hydroxyl or methoxy or Rand Rtogether is carbonyl, all alkyl groups, if substituted with one or more F; Ris H or C(1-6)alkyl; A-Aare N or CR-CR, with no more than two of the four positions A in A-Acan be simultaneously N; R-Rherein; Rand Rherein; or Rand Rfused forming a ring having 5 to 7 atoms by joining Rbeing C(1-6)alkyl or C(2-6)alkenyl. The RORγ compounds can treat RORγ mediated diseases.


Find Patent Forward Citations

Loading…